Global Post-Bariatric Hypoglycemia (PBH) Treatment Market, By Drug Class (Glucosidase Inhibitor, Somatostatin Agonist, Calcium Ion Influx Inhibitor and Others), Mode of Administration (Injectable, Oral, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Hospitals, Homecare, Specialty Clinics, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights : Global Post-Bariatric Hypoglycemia (PBH) Treatment Market
The post-bariatric hypoglycemia (PBH) treatment market is expected to witness market growth at a rate of 7.7% in the forecast period of 2021 to 2028. Data Bridge Market Research report on post-bariatric hypoglycemia (PBH) treatment market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The increase in the prevalence of obesity globally is escalating the growth of post-bariatric hypoglycemia (PBH) treatment market.
Post-Bariatric hypoglycaemia refers to a neuroglycopenia condition that is generally characterized by the low level of plasma glucose less than 54 mg/dL and occurs when patient has undergone bariatric surgery. Bariatric surgery is defined as the surgery which helps in reduction of weight. This neuroglycopenia condition is considred one of the severe complication of bariatric surgery caused by excessive glucagon-like peptide-1 (GLP-1) production that results in hyperinsulinemic hypoglycemia.
The rise in the number of bariatric surgery across the globe acts as one of the major factors driving the growth of post-bariatric hypoglycemia (PBH) treatment market. The increase in the special designation from the regulatory authorities and growing rate of acquisition strategies and company collaborations among manufacturers accelerate the market growth. The increase in demand for bariatric surgeries for the treatment of obesity and related comorbidities, and rise in the body consciousness among population further influence the market growth. Additionally, developments in healthcare infrastructure, growth in obese population, and adoption of unhealthy life choices positively affect the post-bariatric hypoglycemia (PBH) treatment market. Furthermore, development of novel intervention extend profitable opportunities to the market players in the forecast period of 2021 to 2028.
On the other hand, high cost associated with the treatment of post-bariatric hypoglycemia (PBH) and failure of clinical trials during the development stage are expected to obstruct the market growth. Lack of trained medical personnels and stringent safety regulations are projected to challenge the post-bariatric hypoglycemia (PBH) treatment market in the forecast period of 2021-2028.
This post-bariatric hypoglycemia (PBH) treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on post-bariatric hypoglycemia (PBH) treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Post-Bariatric Hypoglycemia (PBH) Treatment Market Scope and Market Size
The post-bariatric hypoglycemia (PBH) treatment market is segmented on the basis of drug class, mode of administration, distribution channel, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of drug class, the post-bariatric hypoglycemia (PBH) treatment market is segmented into glucosidase inhibitor, somatostatin agonist, calcium ion influx inhibitor and others.
- On the basis of mode of administration, the post-bariatric hypoglycemia (PBH) treatment market is segmented into injectable, oral and others.
- On the basis of distribution channel, the post-bariatric hypoglycemia (PBH) treatment market is segmented into hospital pharmacies, retail pharmacies and online pharmacies.
- On the basis of end user, the post-bariatric hypoglycemia (PBH) treatment market is segmented into hospitals, homecare, specialty clinics and others.
Global Post-Bariatric Hypoglycemia (PBH) Treatment Market Country Level Analysis
The post-bariatric hypoglycemia (PBH) treatment market is analyzed and market size information is provided by country, drug class, mode of administration, distribution channel and end user as referenced above.
The countries covered in the global post-bariatric hypoglycemia (PBH) treatment market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the post-bariatric hypoglycemia (PBH) treatment market due to the high prevalence of obesity within the region. Asia-Pacific is expected to witness high growth during the forecast period of 2021 to 2028 because of the high population in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The post-bariatric hypoglycemia (PBH) treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Post-Bariatric Hypoglycemia (PBH) Treatment Market Share Analysis
The post-bariatric hypoglycemia (PBH) treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related twin-twin transfusion syndrome treatment market.
The major players covered in the post-bariatric hypoglycemia (PBH) treatment market report are XOMA, Zealand Pharma A/S, Eiger BioPharmaceuticals, Xeris Pharmaceuticals, Inc, Bayer, Emcure Pharmaceuticals, Virtus, Mylan N.V., Strides Pharma Science Limited, Teva Pharmaceutical Industries Ltd, Amneal Pharmaceuticals LLC, Pfizer Inc, Exela Pharma Sciences, LLC, Novartis AG, WOCKHARDT, Fresenius Kabi AG, Sun Pharmaceutical Industries Limited, and Micro Labs Ltd, among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-